Details of the Drug

General Information of Drug (ID: DMLFZHD)

Drug Name

Aclarubicin

Synonyms

Aclacin; Aclacur; Aclarubicine; Aclarubicino; Aclarubicinum; Jaclacin; Aclacinomycin A; Aclucinomycin A; Antibiotic MA 144A; Antibiotic MA 144A1; Antibiotic MA 144G1; MA 144G1; Aclarubicine [INN-French]; Aclarubicino [INN-Spanish]; Aclarubicinum [INN-Latin]; Antibiotic MA144-A1; MA 144-A1; MA-144A1; Acene-1-carboxylate; Aclarubicin (USAN/INN); Aclarubicin [USAN:BAN:INN]; Alpha-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester; 10-epi-Aclacinomycin A

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Anticancer Agents

ATC Code

L01DB04: Aclarubicin

L01DB: Anthracyclines and related substances

L01D: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES

L01: ANTINEOPLASTIC AGENTS

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

#Ro5 Violations (Lipinski): 2

Molecular Weight (mw)

811.9

Logarithm of the Partition Coefficient (xlogp)

3.8

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

Chemical Identifiers

Formula: C42H53NO15
IUPAC Name: methyl (1R,2R,4S)-4-[(2R,4S,5S,6S)-4-(dimethylamino)-5-[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-[(2R,6S)-6-methyl-5-oxooxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1H-tetracene-1-carboxylate
Canonical SMILES: CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O
InChI: InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1
InChIKey: USZYSDMBJDPRIF-SVEJIMAYSA-N

Cross-matching ID

PubChem CID: 451415
ChEBI ID: CHEBI:77980
CAS Number: 57576-44-0
UNII: 74KXF8I502
DrugBank ID: DB11617
TTD ID: D01UBX

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN ; TOP2B_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[3]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Gene/Protein Processing	[3]
DNA fragmentation factor subunit alpha (DFFA)	OTFPFMT8	DFFA_HUMAN	Protein Interaction/Cellular Processes	[4]
E3 ubiquitin-protein ligase XIAP	OT24GP9B	XIAP_HUMAN	Drug Response	[5]
Erythroid transcription factor (GATA1)	OTX1R7O1	GATA1_HUMAN	Gene/Protein Processing	[6]
Glutathione S-transferase P (GSTP1)	OTLP0A0Y	GSTP1_HUMAN	Gene/Protein Processing	[7]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Gene/Protein Processing	[3]
Porphobilinogen deaminase (HMBS)	OT3P47DC	HEM3_HUMAN	Gene/Protein Processing	[6]
Superoxide dismutase (SOD1)	OT39TA1L	SODC_HUMAN	Gene/Protein Processing	[6]
Transcription factor NF-E2 45 kDa subunit (NFE2)	OTLM94BI	NFE2_HUMAN	Gene/Protein Processing	[6]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2	Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines. Anticancer Drug Des. 2001 Dec;16(6):305-15.
3	Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumours. Mutat Res. 2010 Jul 19;700(1-2):1-10. doi: 10.1016/j.mrgentox.2010.04.013. Epub 2010 Apr 24.
4	Comparison of anthracycline-induced death of human leukemia cells: programmed cell death versus necrosis. Apoptosis. 2002 Dec;7(6):537-48. doi: 10.1023/a:1020647211557.
5	Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 2000 May;6(5):1796-803.
6	Oxidative stress involvement in chemically induced differentiation of K562 cells. Free Radic Biol Med. 2000 Jan 1;28(1):18-27.
7	Expression of glutathione S-transferase P1-1 in differentiating K562: role of GATA-1. Biochem Biophys Res Commun. 2003 Nov 28;311(4):815-21.